invest.birchbiomed.com Open in urlscan Pro
208.109.41.98  Public Scan

Form analysis
1 forms found in the DOM

POST /?tnames=10302-clinical_3414_16504469018&utm_campaign=BIRCH_i2i&utm_source=1032&utm_medium=nlspon&utm_content=clinincal#gf_1

<form method="post" enctype="multipart/form-data" target="gform_ajax_frame_1" id="gform_1" action="/?tnames=10302-clinical_3414_16504469018&amp;utm_campaign=BIRCH_i2i&amp;utm_source=1032&amp;utm_medium=nlspon&amp;utm_content=clinincal#gf_1"
  data-formid="1" novalidate="">
  <div class="gform-body gform_body">
    <div id="gform_fields_1" class="gform_fields top_label form_sublabel_below description_below validation_below">
      <div id="field_1_3" class="gfield gfield--type-email gravity-forms-parent field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible" data-js-reload="field_1_3"><label
          class="gfield_label gform-field-label" for="input_1_3">Email</label>
        <div class="ginput_container ginput_container_email">
          <input name="input_3" id="input_1_3" type="email" value="" class="large" aria-invalid="false">
        </div>
      </div>
      <div id="field_1_4" class="gfield gfield--type-hidden gfield--width-full gform_hidden field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible" data-js-reload="field_1_4">
        <div class="ginput_container ginput_container_text"><input name="input_4" id="input_1_4" type="hidden" class="gform_hidden" aria-invalid="false" value=""></div>
      </div>
    </div>
  </div>
  <div class="gform_footer top_label"> <input type="submit" id="gform_submit_button_1" class="gform_button button gform-button--width-full" value="Get Your Investor Presentation"
      onclick="if(window[&quot;gf_submitting_1&quot;]){return false;}  if( !jQuery(&quot;#gform_1&quot;)[0].checkValidity || jQuery(&quot;#gform_1&quot;)[0].checkValidity()){window[&quot;gf_submitting_1&quot;]=true;}  "
      onkeypress="if( event.keyCode == 13 ){ if(window[&quot;gf_submitting_1&quot;]){return false;} if( !jQuery(&quot;#gform_1&quot;)[0].checkValidity || jQuery(&quot;#gform_1&quot;)[0].checkValidity()){window[&quot;gf_submitting_1&quot;]=true;}  jQuery(&quot;#gform_1&quot;).trigger(&quot;submit&quot;,[true]); }">
    <input type="hidden" name="gform_ajax" value="form_id=1&amp;title=&amp;description=&amp;tabindex=0&amp;theme=orbital">
    <input type="hidden" class="gform_hidden" name="is_submit_1" value="1">
    <input type="hidden" class="gform_hidden" name="gform_submit" value="1">
    <input type="hidden" class="gform_hidden" name="gform_unique_id" value="">
    <input type="hidden" class="gform_hidden" name="state_1" value="WyJbXSIsImY4YzE2NjExMjJhYjlmZjc5YjY3Yjk0ZjMyYTI1M2NlIl0=">
    <input type="hidden" class="gform_hidden" name="gform_target_page_number_1" id="gform_target_page_number_1" value="0">
    <input type="hidden" class="gform_hidden" name="gform_source_page_number_1" id="gform_source_page_number_1" value="1">
    <input type="hidden" name="gform_field_values" value="">
  </div>
</form>

Text Content

Skip to content
 * HOME
 * MARKET
 * TERMS
 * FAQ
 * DISCUSSIONS


 * HOME
 * MARKET
 * TERMS
 * FAQ
 * DISCUSSIONS

 * HOME
 * MARKET
 * TERMS
 * FAQ
 * DISCUSSIONS


 * HOME
 * MARKET
 * TERMS
 * FAQ
 * DISCUSSIONS

Crowdfunding an Investment in Therapeutic Healing


LIMITED CHANCE FOR INVESTORS LOOKING FOR A POTENTIAL BIOTECH WINDFALL: THE
FUTURE OF HEALING

45% of the deaths in the industrialized world, according to the National Library
of Medicine, stem from a single condition: fibrosis.[1]

Yet what you’re about to see…

Could help make that a thing of the past, thanks to an under-the-radar firm that
could quickly catch the attention of Big Pharma.

Its treatments could usher in a futuristic world of healing.


INVEST NOW
$5.00
Share Price
$1,000*
Min. Investment
* a 3.5% investor processing fee will be added to all investments
Total Investment to Date
$248,910.00

 * Form 1-A
 * Offering Circular
 * Investor Education

 * Form 1-A
 * Offering Circular
 * Investor Education

Where not only millions of deaths from fibrosis could be a thing of the past…

But also advancing mankind forward to a newer, faster form of healing their
bodies and reversing damage. Helping those with …

Reversing Type 1 diabetes…potentially for millions with a single short-term
treatment![2]

Alopecia Areata[3]… 160 million people suffering from … this distressing,
psychosocial autoimmune hair loss disorder …

And the countless number of us who have scars on our skin…

All from a cutting-edge form of healing… one that Business Insider calls,
“first-of-its-kind” and “groundbreaking”.[4]

Most people, with the exception of a few majors in the biotech industry, don’t
have a clue it exists and is ready to go to market with its cosmetic products.

Then again… most don’t understand just how fast medicine is progressing.

The FDA is currently fast-tracking drugs faster than ever.[5]

AI is literally inventing potential new drugs as MIT recently unveiled.[6]

All of this means the pipeline from discovery to drug is moving quicker than
ever.[7] What used to take years… now takes a fraction of that time.

Which is why many of the top biotech companies in the world are now in overdrive
mode. And investors need to be taking note of this.

A small stake today… in the right companies… pioneering the right cures….

It could be the equivalent to penicillin being discovered by Alexander Fleming
100 years ago.[8]

Biotech is what minted the world’s first billionaire.[9] Which is why it’s no
surprise many of today’s billionaires are rushing back in, to expand their
empires even more.[10]

And today, a unique opportunity has emerged once again…

A company is introducing the future of healing…

This company is currently seeking to raise $10 million and a potential direct
listing on the NASDAQ.*

The profit ramifications could be enormous … especially for a disruptor company.

INVEST NOW

Its treatments could:

 * Help prevent up to 45% of the deaths in the industrialized world… unlocking
   up to $96 billion in total addressable market value… [11]
 * Reverse Type 1 Diabetes… for which there is no cure and is increasing year
   over year.[12a] – an $8 billion market.[12b]
 * Potentially cure autoimmune disorders such as alopecia areata – a potential
   $22 billion market.[13]



Several leading cosmetic and over-the-counter companies are already discussing
how a non-prescription strength version of this scar treatment could benefit
their customers.

 * This young company could completely disrupt the scar treatment industry – a
   $2.3 billion market.[14]
 * And the beauty market, valued at $114 billion in America alone.[15]

And this is not a what if scenario.

Discussions with major cosmetics companies are already in motion.

Clinical trials have already progressed significantly … some having completed
phase 2 and others on their way to Phase 3.[16] And as mentioned earlier, the
FDA is greenlighting more medicines than ever in the phase 3.[17]

So if you’re ready to find out about the future of healing, BirchBioMed, a
company that could soon be a HUGE player in the world of biotech, should be on
your radar


SEE FOR YOURSELF THE FUTURE HEALING

Those who’ve carried a scar know how embarrassing and confidence killing it can
be.

A before and after picture is all it takes to understand BirchBioMed is doing
something uniquely ground-breaking.

Internationally recognized burn surgeon Anthony Papp, the doctor who evaluated
this treatment during its phase studies, revealed to News Wire:

“As a burn surgeon, I see the horrific effects of scarring every day… There is
no therapeutic on the market today that has shown the unequivocal results that
FS2 has demonstrated in robust pre-clinical scar models.”[18]

And this is not just burns.

Post op scar tissue has also responded to their treatment…

As well as mature scar tissue that had been in place for months and years.

Meaning for the billions of people who have a childhood scar… or suffered a
workplace accident they wish they could forget… or just carry a reminder of a
past surgery… the option to remove it through a natural healing process being
pioneered by this firm could be in store…

And the applications go far beyond just scar tissue.

Few outside the medical field know this, but over 45% of the deaths in the
industrialized world are caused by severe fibrosis.[19] This includes everything
from the heart, lungs, liver, the intestinal tract… even the skin and nervous
system.

INVEST NOW

The fact is that BirchBioMed has come up with something that could drastically
reduce fibrosis. This technology is starting to put them on the radar of Big
Pharma globally.

Graphic Source[20]

The reason they have the potential to reduce the global-killer that is fibrosis
so amazingly is thanks to an incredible new, patent-protected science called
FS2.

This is a naturally occurring molecule in the healing process. One that signals
the body to stop the formation of scars and to break down existing scars.



FS2 has also prevented buildup of scar tissue nodules in the lungs as you can
see here.


INVEST NOW

FS2 is also showing promising results to help cure autoimmune disorders, such as
Type 1 Diabetes and Alopecia Areata (autoimmune hair loss).

Imagine a world where diseases once considered insurmountable obstacles are mere
bumps in the road on the path to wellness.

And now imagine if you, as an investor, had access to become a shareholder
BEFORE the company went public. While BirchBioMed may be priced like a start-up,
they have completed phase 1 and phase 2 clinical trials and just received
regulatory approval for a phase 2b/phase 3 clinical trial, making them a
potential disruptor in the biotech industry. the biotech industry.

Before the company disrupts the healing process of virtually every scar remedy
in the modern medical world.

Moments like these are rare for biotech investors.

Just consider if you’d invested $1,000 into Johnson and Johnson at the very
beginning, when they IPO’d … that small bet would have paid off massively with a
$10 million fortune.[21]

Pfizer has gone from 27 cents at IPO to more than $27 today; handing early
investors over 100 times their money.[22]**

When you get in on the right company, the long-term benefits can be
life-changing.

With this many applications, the company is compelling not only from an
investing standpoint, but even from an M&A standpoint.

Any one of the Big Pharma names could buy up this company with a single stroke
of one of their accountant’s pens.

Making this limited window that you have to get in pre-public listing
potentially very impactful for you as an investor.

Because this truly is The Future of Healing …

Imagine walking into a CVS or a Walgreens …

Seeing this company’s technology on the shelves, side by side along giants like
Johnson and Johnson, Pfizer and Bristol Meyers Squibb… knowing that you had the
chance to invest before this company could go public.*

This could very well be one of the most profitable investments you ever stumble
upon, just due to the sheer variety of all its applications.

Soon it could spread to doctors’ offices, hospitals, outpatient treatment,
cosmetic surgeons offices and beyond… unlocking the potential of this $96
billion market.

For investors, this could be the final opportunity to invest in BirchBioMed
before going public.

The company is only looking to raise $10 million before its planned listing on
the NASDAQ.

And raising $10 million is not outside the experience of this company …

Quite the contrary, BirchBioMed is used to cashing millions of dollars in checks
coming their way…


THE POWER OF PARTNERSHIP AND A STACKED BOARD

BirchBioMed has received over $6 million in grants and donations, including from
the Canadian Institute of Health Research, Juvenile Diabetes Research
Foundation, National Alopecia Areata Foundation, WorkSafeBC (British Columbia)
and some of the world’s major firefighters associations.[23]

The Canadian Government has played an instrumental role in supporting
BirchBioMed! The Canadian government spends $8,500 per Canadian resident on
healthcare, for a whopping $330 billion, so if they can get that number lower
with a company like BirchBioMed, it’s a win-win for everyone.[24]



It’s no accident they’re coming into these millions: the company is spearheaded
by one of the most stacked management boards in the industry.

Doctors, former CEOs of biotech companies and C-suite executives of major pharma
companies, even combat experienced military doctors.




In short, the team isn’t just led by flashy suits trying to drive a medicine to
market – it’s led by medical professionals who understand what the majority of
patients want and need

It’s led by proven C-level executives who know what it takes to take biotechs
public.

And most importantly for investors, by a management team that has shown results.

But this opportunity will not remain open forever. Time is ticking on the chance
to get in on this round of funding before the company’s planned public listing.

Once the company hits its $10 million funding round, that’s it. Your chance to
get in on this round will be gone forever.

INVEST NOW


LIMITED CHANCE FOR SMART INVESTORS TO GET IN BEFORE PUBLIC LISTING

If you get in on the bare minimum round of funding, it’s no stretch that $1,000
could change your life.

If you agree that BirchBioMed could be onto something big, you should consider
investing before this round of funding closes.

If you’ll remember earlier… just $1,000 into JNJ at their IPO yielded more than
$10,000,000 over the course of time.[25]

Pfizer turned every $1,000 invested into $100,000!

Of course, past performance is no guarantee of future results.

But with nothing else like this on the market, investors who are interested in
potential biotech fortunes should keep BirchBioMed on their radars.

 All you have to do is get in during this round of crowdfunding, during the Reg
A phase.

If you’re unfamiliar with Reg A deals…

This is one of the best ways for everyday investors to get into pre-public
companies like BirchBioMed and the future of healing.

Since first becoming an option for investors 12 years ago, Reg A deals like this
have been the ultimate way for small startups to raise up to $50 million.[26]

Not to mention, the company already has the attention of major name brand
cosmetics companies that have expressed interest in this anti-scarring treatment
for their customers.

The signs are pointing to an exciting industry shift – and this company could be
a major winner.

BirchBioMed is on track to revolutionize not just the future of healing, but the
landscape of diabetes treatment, alopecia areata and more.

The reasons to keep this company on your radar as an investor seem almost
endless.


5 REASONS TO INVEST IN BIRCHBIOMED RIGHT NOW

 * Groundbreaking Innovation: BirchBioMed's revolutionary treatment, FS2, isn't
   just another product in the market. Business Insider has called it one of a
   kind and rightfully so: It has the potential to transform lives across
   multiple medical fronts[27]. With its potential ability to accelerate
   healing, prevent scarring, and address a spectrum of ailments from fibrosis
   to autoimmune disorders, FS2 represents a breakthrough that could redefine
   medical treatment paradigms.

 * Explosive Market Potential: BirchBioMed's FS2 isn't just limited to medical
   applications; it could be poised to revolutionize the $2 billion scar
   treatment industry as well.[28]
   
   The release of an OTC version of FS2 could be backed by a major industry
   player. This could herald a new era in cosmetic products entirely.

 * Exponential Growth Projections: Even a conservative estimate of BirchBioMed
   capturing just one percent of its addressable market translates into
   substantial growth.

 * Upcoming NASDAQ Listing*: BirchBioMed intends to begin their journey to the
   NASDAQ in the near-future.
   
   As BirchBioMed prepares to make its mark on one of the world's most
   prestigious stock exchanges, investors have a unique chance to get in on the
   ground floor of a biotech revolution with huge potential.
   
   So as this stock captures the attention of the biotech industry, you’ll
   already be in before almost anyone else.

 * Private Equity Outperforms Public Markets: research has shown throughout time
   that private equity has outperformed public markets.[29] This is an exciting
   chance to get in on a biotech that is capturing the attention of Big Pharma
   and cosmetics giants alike.

Game-changing technology, expansive market potential, and life-saving impact,
BirchBioMed presents a rare investment opportunity that demands attention.

Don’t miss out on being part of this transformative journey. Invest in
BirchBioMed today and you could be a catalyst for change in the world of biotech
and cosmetics.

This is your chance to get in before it goes public and potentially turn
something as small as $1,000 into a windfall.

Don’t miss out on this round of funding for BirchBioMed before it closes.

*Listing on the NASDAQ pending approval

**Past performance is not indicative of future results. Birch BioMed cannot
guarantee returns or future growth.

INVEST NOW


TERMS

 * Security type: Common shares
 * Security price: $5
 * Ancillary fee: 3.5%
 * Minimum investment amount: $1,000 (200 common shares)


INVESTOR EDUCATION


FAQS

 1. What is your commercialization strategy?
    We provide an outline of our go-to market and commercialization approach in
    our most recent investor deck that can be found on our website.
    
    
 2. What is your exit strategy?
    We are a technology-transfer company. As such, we have been focused on
    developing our technologies to the point that they are prime candidates for
    M&A (Mergers and Acquisition) or out-licensing. Our exit strategy in the
    future could be a public offering (IPO) or M&A. We will share any
    information that can be made public with insider investors first. While we
    are under certain confidentiality agreements and SEC regulations that
    prohibit us from disclosing certain information, we kindly ask that you
    refer to the list of BirchBioMed™ SEC filings on EDGAR, including the
    filings that relate directly to the Regulation A+ offering.
    
    
 3. Who are your current business contacts?
    Most of our customer relationships are under NDAs and confidentiality
    agreements. That said, we are in discussions with several top-tier cosmetics
    and pharmaceutical companies about potential M&A or out-licensing. As soon
    as we are able to make public announcements, we will share this with our
    insider investors first.
    
    
 4. Where can we access the company financials?
    All of our financials are public information. You can find our most recent
    financials, along with our other recent updates on BirchBioMed™ SEC’s EDGAR
    webpage.
    
    
 5. What are your plans for an IPO?
    We are a private, pre-IPO company with no exchange on which to trade shares.
    Upon completion of our Regulation A+ offering, we intend to explore several
    potential go-public possibilities, such as listing on a public exchange
    (e.g., the Nasdaq). Upon approval from the SEC to list, our shareholders
    would be free to sell their shares. At this point, however, there is no set
    date for such a listing or any follow-on offerings. We will continue to
    include any new details that can be shared regarding developments in email
    updates to investors.
    
    
 6. How do I access information on the shares I purchased?
    You can access all investment information, including number of shares and
    DRS statement paperwork by logging into the portal by which you made your
    investment. If you need any changes, such as a beneficiary address change,
    please contact: https://odysseycontact.com/ if you made your investment
    through DealMaker. 
    
    
    
    
    
    Click I am a Shareholder or the holder of other Securities
    Then choose the subject of the inquiry.
    You may also call us 1-866-350-1993.
    
    

 7. With the Regulation A+ offering, can I cash out whenever I want to?
    At this time, no, as we are still a private, pre-IPO company with no
    exchange on which to trade shares.
    
    
 8. How has BirchBioMed™ share price changed over time?
    2016 Private Placement Shares (Regulation D)               $1.00 per share
    2020 Private Placement Shares (Regulation D)               $2.00 per share
    2023 Convertible Note Warrants (Exercise Price)            $2.50 per share
    2024 Current Offering (Reg. A+)                                         
     $5.00 per share


WANT TO LEARN MORE ABOUT BIRCHBIOMED'S BREAKTHROUGH THERAPEUTIC HEALING?

Email






By signing up above you will receive the free report and investor updates from
BirchBioMed.
You can unsubscribe at any time..




SOURCES

Sources

[1] https://pubmed.ncbi.nlm.nih.gov/33239795/ 

[2] https://www.cdc.gov/diabetes/data/statistics-report/index.html

[3]
https://www.pfizer.com/disease-and-conditions/alopecia-areata#:~:text=In%20total%2C%20an%20estimated%206.7,people%20globally%20have%20alopecia%20areata.&text=This%20condition%20affects%20some%20populations,have%20it%20than%20white%20people.

[4]https://markets.businessinsider.com/news/stocks/birchbiomed-is-cleared-to-begin-first-of-its-kind-phase-ii-clinical-trial-for-ground-breaking-anti-scarring-drug-1016018500?op=1

[5] https://www.advisory.com/daily-briefing/2019/07/10/fast-tracked

[6]
https://www.technologyreview.com/2023/02/15/1067904/ai-automation-drug-development/

[7] https://www.nature.com/articles/s41587-024-02166-7

[8]
https://www.sciencemuseum.org.uk/objects-and-stories/how-was-penicillin-developed#:~:text=In%201928%20Dr%20Alexander%20Fleming,chemical%20that%20could%20kill%20bacteria.

[9]
https://www.fool.com/investing/general/2013/09/28/the-birth-of-pharmaceuticals-and-the-worlds-first.aspx

[10]
https://investorplace.com/2024/03/billionaires-biotech-bets-3-stocks-dominating-bill-gates-portfolio/

[11] Investor Deck – Page 11

[12a]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141720/#:~:text=The%20worldwide%20incidence%20of%20type,are%20not%20yet%20fully%20understood.

[12b]
https://www.expertmarketresearch.com/reports/type-1-diabetes-market

[13] https://www.futuremarketinsights.com/reports/alopecia-treatment-market

[14] https://www.grandviewresearch.com/industry-analysis/scar-treatment-market

[15]
https://www.mckinsey.com/industries/retail/our-insights/the-beauty-market-in-2023-a-special-state-of-fashion-report

[16] Investor Deck – Page 21

[17] https://www.nature.com/articles/s41587-024-02166-7

[18]
https://www.newswire.ca/news-releases/birchbiomed-is-cleared-to-begin-first-of-its-kind-phase-ii-clinical-trial-for-ground-breaking-anti-scarring-drug-674280503.html

[19] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749507/

[20] See Page 11 from Investor Deck: https://www.grandviewresearch.com;
https://www.marketresearchfuture.com/sample_request/8199;
https://globenewswire.com/news-release/2020/12/09/2142566/0/en/Global-Alpoecia-Market-is-Forecast-to-Deliver-a-CAGR–of-5-1-Between-2019-and-2027.html

[21]
https://www.fool.com/investing/2022/10/19/invest-1000-johnson-johnson-ipo-1944-how-much-now/

[22] https://www.macrotrends.net/stocks/charts/PFE/pfizer/stock-price-history

[23] Investor Deck – page 16

[24] https://www.cihi.ca/en/national-health-expenditure-trends-2022-snapshot

[25]
https://www.fool.com/investing/2022/10/19/invest-1000-johnson-johnson-ipo-1944-how-much-now/

[26]
https://www.entrepreneur.com/finance/why-founders-are-turning-to-reg-a-and-cf-to-raise-money-in/468339

[27]
https://markets.businessinsider.com/news/stocks/birchbiomed-is-cleared-to-begin-first-of-its-kind-phase-ii-clinical-trial-for-ground-breaking-anti-scarring-drug-1016018500?op=1

[28] https://www.grandviewresearch.com/industry-analysis/scar-treatment-market

[29]
https://addx.co/insights/why-private-markets-tend-to-outperform-public-every-time-even-in-down-markets/



Equity crowdfunding investments in private placements, and start-up investments
in particular, are speculative and involve a high degree of risk and those
investors who cannot afford to lose their entire investment should not invest in
start-ups. Companies seeking startup investment through equity crowdfunding tend
to be in earlier stages of development and their business model, products and
services may not yet be fully developed, operational or tested in the public
marketplace. There is no guarantee that the stated valuation and other terms are
accurate or in agreement with the market or industry valuations. Further,
investors may receive illiquid and/or restricted stock that may be subject to
holding period requirements and/or liquidity concerns.

DealMaker Securities LLC, a registered broker-dealer, and member
of FINRA | SIPC, located at 4000 Eagle Point Corporate Drive, Suite 950,
Birmingham, AL 35242, is the Intermediary for this offering and is not an
affiliate of or connected with the Issuer. Please check our background on
FINRA’s BrokerCheck.

DealMaker Securities LLC does not make investment recommendations.

DealMaker Securities LLC is NOT placing or selling these securities on behalf of
the Issuer.

DealMaker Securities LLC is NOT soliciting this investment or making any
recommendations by collecting, reviewing, and processing an Investor’s
documentation for this investment.

DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor
Disqualification reviews of the Issuer, and confirms they are a registered
business in good standing.

DealMaker Securities LLC is NOT vetting or approving the information provided by
the Issuer or the Issuer itself.

AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE
SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY
MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. THE OFFERING
CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT IS AVAILABLE HERE.

THIS WEBSITE MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO,
AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS
INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF,
ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S
MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,”
“PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS
ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT
MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO
RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER
MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE
CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH
SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE
ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT
EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF
UNANTICIPATED.

* See our Important Notice and Disclaimer above for a detailed discussion on
compensation, risks, atypical results, and more. 

You should rely only on the information contained in our Offering Circular and
the Offering Statement of which it forms a part, as each may be amended and
supplemented from time to time, in making your decision to purchase our
securities. We have not authorized anyone to provide you with different
information. Our website and the information contained on, or that can be
accessed through, our website will not be deemed to be incorporated by reference
in, and are not considered part of, the Offering Circular or the Offering
Statement of which it forms a part. In the event of a discrepancy between our
website and the Offering Circular and the Offering Statement of which it forms a
part the Offering Circular and Offering Statement controls.

Contact Us

Scroll to Top

Notifications